IP Library › Granted Patent US 11,064,684
Granted Patent B2
US 11,064,684 · App. 16/531,351 · Granted Jul 20, 2021

Multiplexed genome editing

Inventors: George M. Church (Brookline, MA); Luhan Yang (Somerville, MA); Marc Guell (Barcelona, ES)
Assignee: President and Fellows of Harvard College
A01K67/0275A01K67/0273A01K67/0276C12N7/00C12N9/22C12N15/11C12N15/1132C12N15/63C12N15/85C12N15/8509C12N15/907A01K2207/05A01K2207/10A01K2227/108A01K2267/025C07H21/02C07H21/04C12N2310/20C12N2740/10062C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,064,684
App. No.
16/531,351
Granted
Jul 20, 2021
Kind
B2
Abstract

A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.

Claims (12)

1. A genetically engineered porcine cell in which at least 97% of the porcine endogenous retrovirus (“PERV”) pol genes comprise a genetically engineered genomic indel.

2. The genetically engineered porcine cell of claim 1 , wherein 100% of the PERV pol genes comprise a genetically engineered genomic indel.

3. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell exhibits at least a 1000-fold reduction in PERV transmission as evidenced by co-culturing a human cell with the genetically engineered porcine cell as compared to co-culturing a human cell with a wild-type porcine cell.

4. The genetically engineered porcine cell of claim 3 , wherein the human cell is HEK293.

5. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered genomic indel is observed by sequencing.

6. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell contains intact PERV gag and/or env genes.

7. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is from an embryo.

8. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is a stem cell, zygote, or germ line cell.

9. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is an embryonic stem cell or pluripotent stem cell.

10. The genetically engineered porcine cell of claim 1 , wherein the genetically engineered porcine cell is a somatic cell.

11. A progeny cell derived from the genetically engineered porcine cell of claim 1 .

12. A composition comprising a plurality of the progeny cell of claim 11 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2019
From: CHURCH, GEORGE M.; GUELL, MARC; YANG, LUHAN
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 050160/0724 →
Continuity (3)
Continuation 15766551
Provisional Application 62239239 · Oct 8, 2015
Related Publication 20190350177A1 · Nov 21, 2019
Cited By (2)
US 12,630,838 US 12,637,690